Overview
Aurovitas Pharma Polska is a pharmaceutical company and part of the Aurobindo Pharma group. It offers generic prescription (Rx) and over-the-counter (OTC) medicines across 22 areas.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2026.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-04-18. Active
21 1030 1508 0000 0008 1711 0037
27 1600 1462 1743 0884 7000 0001- 39 1030 1508 0000 0008 1711 0004
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 733.4KPLN 733,355 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 28, 2025 | Return of additional payments |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Trademarks
Aurovitas Pharma Polska holds 133 active trademarks registered with the Polish Patent Office. 10 applications are pending. 7 marks have expired or were not registered. The first mark was filed in 2008.
| Mark | Protected until | |
|---|---|---|
| AUROTHERAVIS(word) | Feb 19, 2036 | |
| FLEXISTAV(word) | Feb 3, 2036 | |
| AUROCORABIA(word) | Jan 23, 2036 | |
| LIPIFORMA BERGAMIA MAX(word) | Jan 23, 2036 | |
| LIPIFORMA PLUS+(word) | Jan 23, 2036 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board – one member of the management board acting independently. In the case of a multi-member management board – two members of the management board acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Agile Pharma B.v. | 91,509 | $2,471,880.06 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Natur Produkt Zdrovitsp. z o.o. | $205,379,396.79 | zdrovit.pl | ||
| Astellas Pharmasp. z o.o. | $220,199,081.58 | astellas.com | ||
| Gilead Sciences Polandsp. z o.o. | $150,844,944.19 | gilead.com | ||
| Przedsiębiorstwo Zaopatrzenia Aptek Multi PharmeS.A. | $146,864,520.79 | multipharme.pl | ||
| Amgensp. z o.o. | $145,068,009.51 | amgen.pl | ||
| Zentiva Polskasp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Przedsiębiorstwo Zaopatrzenia Farmaceutyczno-Weterynaryjnego Centrowetsp. z o.o. | $92,728,267.63 | grupacentrowet.pl | ||
| Magnapharm Polandsp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Aurepiosp. z o.o. | $39,635,095.48 | aurepio.pl | ||
| Bionorica Polskasp. z o.o. | $19,802,926.77 | bionorica.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-02-28 | PKD change (Removed: 72.11.Z, 72.19.Z; Added: 46.38.Z, 72.1) | |
| 2019-04-08 | Share capital change (8,731,900.00 PLN → 9,150,900.00 PLN) | |
| 2019-01-30 | Share capital change (4,125,700.00 PLN → 8,731,900.00 PLN) | |
| 2017-12-01 | Share capital change (2,357,600.00 PLN → 4,125,700.00 PLN) | |
| 2017-10-19 | Share capital change (1,000,000.00 PLN → 2,357,600.00 PLN) |
FAQ
Last updated: 2026-10-07